Redefining Eosinophilic Oesophagitis (EoE) Control: Elevating Patient Lives Beyond Symptom Suppression

This satellite symposium was organised and sponsored by Sanofi and Regeneron; and is intended for healthcare professionals only. Speakers were compensated for their participation at this event.

The dynamic treatment landscape for eosinophilic oesophagitis (EoE) continues to emphasise symptom relief, often neglecting the underlying progressive nature of the disease. During this symposium, a panel of experts examine proactive and comprehensive disease management, considering the chronic and progressive nature of EoE. 

The pitfalls associated with symptom-only assessment and the importance of regular monitoring through endoscopy and histology are also discussed. The video additionally explores breaking the cycle of episodic treatments with an emphasis on the long-term management of Type 2 inflammation in EoE with dupilumab, illuminating a path for healthcare providers to improve patient’s lives. 

Objectives:   

• Identify patients whose EoE is not fully controlled and the importance of looking beyond symptoms for disease management. 
• Recognise the often cyclical, symptom-based approaches to managing EoE and the potential for a sustained long-term approach to treating EoE, considering the chronic and progressive nature of the disease. 
• Review evidence on symptom control and histologic and endoscopic clinical outcomes for dupilumab in patients with EoE. 

Speakers:

Ulrike von Arnim, MD, PhD (Chair)
Leading Senior Physician, Department of Gastroenterology, Hepatology, and Infectious Diseases
Head of the Outpatient Clinic
University Hospital Magdeburg
Magdeburg, Germany

Milli Gupta, MD, FRCPC
Associate Clinical Professor of Gastroenterology and Hepatology
University of Calgary Cumming School of Medicine
Calgary, Alberta, Canada

To access the full Summary of Product Characteristics of the Product Information, please click here.